LASIK & PRK: still looks good ten years on

Article

LASIK for myopia over -10 D is a safe procedure; myopic regression slows down with time and there is a high rate of best spectacle corrected visual acuity (BSCVA) increase in the long-term.

LASIK for myopia over -10 D is a safe procedure; myopic regression slows down with time and there is a high rate of best spectacle corrected visual acuity (BSCVA) increase in the long-term, according to Jorge Alio, MD and colleagues from the VISSUM Instituto Oftalmológico de Alicante and the Miguel Hernandez University Medical School, Spain.

A total of 196 myopic eyes (118 patients) with a mean preoperative spherical equivalent (SE) of -13.95±2.79 D were included in the study. Myopic LASIK was performed using the VISX 20/20 excimer laser (AMO) with a 6 mm ablation zone. Patients were evaluated at three months, one, two, five and 10 years.

At 10 years follow-up, 82 eyes (42%) were within ±1.00 D and 54 eyes (27.5%) had undergone re-treatments. The mean SE decreased, in eyes that did not receive re-treatments, with a mean rate of -0.25±0.18 D per year that slowed over time. Overall, 124 eyes (63%) demonstrated an increase in BSCVA after 10 years follow-up. Two eyes (1%), with more than 15 D myopic correction, developed corneal ectasia.

…and so does PRK

The same research team also claimed that photorefractive keratectomy (PRK) for myopia over -10 D is a safe procedure with a high rate of BSCVA increase in the long term.

In a further study, 70 eyes (50 patients) with myopia ranging between -10.00 and -17.75 D underwent myopic PRK with the VISX 20/20 excimer laser (AMO) with a 6 mm ablation zone and were followed-up for a ten-year period.

Twenty-eight eyes (40%) were within ±1.00 D at 10 years follow-up and 28 eyes (40%) underwent re-treatments. Mean SE decreased over 10 years at a rate of 0.23±0.30 D per year that slowed down with time. Forty-one eyes (58%) demonstrated an increase in BSCVA after 10 years and only five (7.1%) lost more than two lines of BSCVA. The mean corneal haze score decreased gradually from 0.87±0.83 at three months to 0.16±0.45 at 10 years.

The authors of these two studies suggest that both LASIK and PRK are safe and effective procedures for the correction of high myopia.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.